ArticlemAbs2026

Preclinical development of ABL206, a novel bispecific antibody-drug conjugate targeting B7-H3 and ROR1.

Jung A Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.